Alcon Inc. (ALC) is listed on NYSE and operates in the Medical - Instruments & Supplies industry (Healthcare sector).
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glau...
| Rating | Analysts |
|---|---|
| Strong Buy | 0 |
| Buy | 14 |
| Hold | 10 |
| Sell | 2 |
| Strong Sell | 0 |
Alcon Inc., headquartered in Geneva, Switzerland, is a global eye care company specializing in the research, development, manufacturing, distribution, and sale of eye care products. The company operates through two main segments: Surgical and Vision Care. The Surgical segment provides equipment, instrumentation, diagnostics, and implantables, including intraocular lenses (IOLs) and consumables for surgical procedures. Key products include cataract surgery systems, vitreoretinal products, refractive surgery lasers, and glaucoma filtration devices. The Vision Care segment offers a range of contact lenses, including daily disposable, reusable, and color-enhancing options, as well as ocular health products. These include treatments for dry eye, glaucoma, and ocular allergies, along with contact lens care solutions and ocular vitamins. Alcon's brands include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Originally founded in 1945 as Alcon Universal S.A., the company adopted its current name in December 2001.
Over the past three fiscal years, the company demonstrated a consistent increase in revenue, growing at a compound annual growth rate (CAGR) of 4.9% from $9.46 billion in 2023 to $10.40 billion in 2025. Despite this revenue growth, the company's net margin experienced a slight compression, decreasing by 0.9 percentage points from 10.3% to 9.4%, indicating some pressure on profitability. However, operating margin showed improvement, expanding by 2.1 percentage points to 13.1%, suggesting effective cost management or operational efficiencies. The company's cash generation capabilities significantly strengthened, with operating cash flow (OCF) increasing at a robust CAGR of 27.9%, reaching $2.27 billion in 2025. Free cash flow (FCF) saw an even more impressive rise, growing at a CAGR of 79.4% to $1.73 billion, with FCF margin expanding by 10.9 percentage points to 16.6%. This indicates a strong ability to convert earnings into cash, further supported by an increasing cash conversion ratio (CCR), which reached 2.32, highlighting high-quality earnings. The company's capital efficiency improved as well, with capex intensity consistently decreasing to 5.2%, reflecting a capital-light business model. Additionally, the company's net debt position decreased from $4.04 billion to $3.72 billion, indicating improved financial leverage. Despite the slight inconsistency in earnings per share (EPS), which grew modestly from $1.96 to $1.98, the reduction in share count through buybacks was not material enough to significantly impact per-share metrics. Overall, the company has shown strong cash generation and operational improvements, albeit with some margin pressures.
Recent developments for Alcon (ALC) are highlighted by a strategic decision to reject a takeover bid from STAAR Surgical, justified by strong preliminary Q1 revenues. This financial performance underscores Alcon's confidence in its market position and growth prospects. In product news, Alcon launched the Clareon TruPlus, an enhanced design monofocal and toric intraocular lens (IOL), at the ASCRS 2026, which has positively impacted its stock performance. Additionally, Alcon has entered into an arrangement agreement with Mexican Gold Mining Corp. to create a diversified precious metals exploration company, indicating a strategic diversification move. On the trading front, Representative Josh Gottheimer disclosed selling between $1,001 and $15,000 in Alcon shares on March 12, 2026, as part of a series of transactions involving other stocks. These activities suggest routine portfolio adjustments rather than a shift in company outlook. Overall, Alcon's recent actions reflect a focus on strengthening its core business while exploring new strategic opportunities.